Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

Summary

To assess the safety and efficacy of two forms of Talazoparib therapy (injections subcutaneously Talazoparib and oral form for the treatment in the equivalent therapeutics dose

Timeline

Start

2022-11-10

Primary completion

2023-12-10

Completion

2024-01-10

Outcome

Outcome not reported

Stopped: “the company is liquidated”

Drugs

Indications